– Antiretroviral, HIV nucleotide reverse transcriptase inhibitor
– HIV infection, in combination with other antiretrovirals
– Post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP), in combination with lamivudine (3TC) or emtricitabine (FTC)
Forms and strengths
– 300 mg tablet, equivalent to 245 mg of tenofovir disoproxil
Also comes in fixed-dosed combinations containing tenofovir for HIV treatment.
– Child 35 kg and over and adult: 300 mg once daily
– The duration of treatment depends on the efficacy and tolerance of tenofovir.
Contra-indications, adverse effects, precautions
– Administer with caution in patients with renal impairment.
– Monitor renal function. In the event of deterioration of renal function, switch to another antiretroviral.
– Avoid combination (or monitor renal function in the event of combination) with nephrotoxic drugs: aminoglycosides (e.g. gentamicin, streptomycin), amphotericin B, pentamidine, etc.
– May cause:
• gastrointestinal disturbances (nausea, vomiting, diarrhoea, etc.), dizziness, fatigue, skin rash;
• renal impairment, bone loss (osteoporosis, fractures), pancreatitis.
– Administer with caution and monitor use with NSAID (addition of nephrotoxic activity).
– Pregnancy: no contra-indication
– Tenofovir disoproxil is used alone for the treatment of chronic hepatitis B.
– Storage: below 25 °C - -